Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis

Quinfamide is an intraluminal amebicidal with high therapeutic efficacy and low toxicity. Its mechanism of action consists in the intraluminally immobilization of the Entamoeba histolytica trophozoite, and gets its maximum concentration blood level in about 7 hours. The objective of this paper is to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: ROMERO-CABELLO,RAÚL, ROBERT-GUERRERO,LILIA, MARTÍNEZ-BARBABOSA,IGNACIO, VÁZQUEZ-TSUJI,OSCAR, RUIZ-SÁNCHEZ,DORA, TAY-ZAVALA,JORGE, SÁNCHEZ-VEGA,JOSÉ T., CALDERÓN-ROMERO,LETICIA
Lenguaje:English
Publicado: Sociedad Chilena de Parasitología 2005
Materias:
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-77122005000100009
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0717-77122005000100009
record_format dspace
spelling oai:scielo:S0717-771220050001000092005-07-18Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasisROMERO-CABELLO,RAÚLROBERT-GUERRERO,LILIAMARTÍNEZ-BARBABOSA,IGNACIOVÁZQUEZ-TSUJI,OSCARRUIZ-SÁNCHEZ,DORATAY-ZAVALA,JORGESÁNCHEZ-VEGA,JOSÉ T.CALDERÓN-ROMERO,LETICIA Entamoeba histolytica intestinal amebiosis quinfamide therapeutic Quinfamide is an intraluminal amebicidal with high therapeutic efficacy and low toxicity. Its mechanism of action consists in the intraluminally immobilization of the Entamoeba histolytica trophozoite, and gets its maximum concentration blood level in about 7 hours. The objective of this paper is to evaluate the therapeutic action of quinfamide with a single dose in patients having sub-acute or chronic intestinal amebiasis parasitologicaly demonstrated, and to probe its security. Adults with a coproparasitoscopic exam mean concentration-flotation, as well as a complete clinical study were sudied. The cases that result positive because of the identification of parasite forms of E. histolytica and that fulfill the inclusion requirements besides signing the consent letter were given a single 300 mg dose of quinfamide and were kept in the following days under strict observation with coproparasitoscopic control studies realized the next five, six, seven, fourteen and twenty one days. From 568 persons studied, 221 (38.9%) were positive to the presence of intestinal E. histolytica. The coproparasitoscopic control studies showed that in 35 persons (15.84%), the parasite forms continued to be in the feces; and 186 persons (84.16%) corresponded to negativized cases. The clinical follow up never revealed the presence of secondary effects with the administration of this drug. In conclusion, the therapeutic efficacy of a single dose of quinfamide in the treatment of E. histolytica infection was good in comparison with the quinfamide administration of the same dose but in three intakes a dayinfo:eu-repo/semantics/openAccessSociedad Chilena de ParasitologíaParasitología latinoamericana v.60 n.1-2 20052005-06-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-77122005000100009en10.4067/S0717-77122005000100009
institution Scielo Chile
collection Scielo Chile
language English
topic Entamoeba histolytica
intestinal amebiosis
quinfamide
therapeutic
spellingShingle Entamoeba histolytica
intestinal amebiosis
quinfamide
therapeutic
ROMERO-CABELLO,RAÚL
ROBERT-GUERRERO,LILIA
MARTÍNEZ-BARBABOSA,IGNACIO
VÁZQUEZ-TSUJI,OSCAR
RUIZ-SÁNCHEZ,DORA
TAY-ZAVALA,JORGE
SÁNCHEZ-VEGA,JOSÉ T.
CALDERÓN-ROMERO,LETICIA
Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
description Quinfamide is an intraluminal amebicidal with high therapeutic efficacy and low toxicity. Its mechanism of action consists in the intraluminally immobilization of the Entamoeba histolytica trophozoite, and gets its maximum concentration blood level in about 7 hours. The objective of this paper is to evaluate the therapeutic action of quinfamide with a single dose in patients having sub-acute or chronic intestinal amebiasis parasitologicaly demonstrated, and to probe its security. Adults with a coproparasitoscopic exam mean concentration-flotation, as well as a complete clinical study were sudied. The cases that result positive because of the identification of parasite forms of E. histolytica and that fulfill the inclusion requirements besides signing the consent letter were given a single 300 mg dose of quinfamide and were kept in the following days under strict observation with coproparasitoscopic control studies realized the next five, six, seven, fourteen and twenty one days. From 568 persons studied, 221 (38.9%) were positive to the presence of intestinal E. histolytica. The coproparasitoscopic control studies showed that in 35 persons (15.84%), the parasite forms continued to be in the feces; and 186 persons (84.16%) corresponded to negativized cases. The clinical follow up never revealed the presence of secondary effects with the administration of this drug. In conclusion, the therapeutic efficacy of a single dose of quinfamide in the treatment of E. histolytica infection was good in comparison with the quinfamide administration of the same dose but in three intakes a day
author ROMERO-CABELLO,RAÚL
ROBERT-GUERRERO,LILIA
MARTÍNEZ-BARBABOSA,IGNACIO
VÁZQUEZ-TSUJI,OSCAR
RUIZ-SÁNCHEZ,DORA
TAY-ZAVALA,JORGE
SÁNCHEZ-VEGA,JOSÉ T.
CALDERÓN-ROMERO,LETICIA
author_facet ROMERO-CABELLO,RAÚL
ROBERT-GUERRERO,LILIA
MARTÍNEZ-BARBABOSA,IGNACIO
VÁZQUEZ-TSUJI,OSCAR
RUIZ-SÁNCHEZ,DORA
TAY-ZAVALA,JORGE
SÁNCHEZ-VEGA,JOSÉ T.
CALDERÓN-ROMERO,LETICIA
author_sort ROMERO-CABELLO,RAÚL
title Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
title_short Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
title_full Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
title_fullStr Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
title_full_unstemmed Evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
title_sort evaluation of the efficacy and security of quinfamide administered in a single dose of 300 mg in adult patients with intestinal amebiasis
publisher Sociedad Chilena de Parasitología
publishDate 2005
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-77122005000100009
work_keys_str_mv AT romerocabelloraul evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT robertguerrerolilia evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT martinezbarbabosaignacio evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT vazqueztsujioscar evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT ruizsanchezdora evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT tayzavalajorge evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT sanchezvegajoset evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
AT calderonromeroleticia evaluationoftheefficacyandsecurityofquinfamideadministeredinasingledoseof300mginadultpatientswithintestinalamebiasis
_version_ 1718444088695455744